Monday, September 22, 2014

Dulaglutide a new antidiabetic drug for type 2 diabetes

Once a week subcutaneous injection which can keep your type 2 diabetes under check.

Type 2 diabetes patient have to take regular medication in order to keep his blood sugar level under control, and regular skipping a dose of antidiabetic medicines may prove very critical.
Now a once a week subcutaneous injection can take care this too, which alone will help to keep blood sugar under control in type 2 diabetes, such drug is now available, US FDA have approved a new antidiabetic drug for treatment of Type 2 diabetes.

Drug is Dulaglutide , a glucagon-like peptide-1 (GLP-1) receptor agonist, GLP1 help in mobilizing blood glucose from blood to tissue cells, and drug dulaglutide increase the activity of glucagon-like peptide-1 (GLP-1) receptors for hormone glucagon-like peptide-1 (GLP-1).
Trulicity is brand name of the drug approved by US FDA which contains dulaglutide, it is manufactured by Eli Lilly and Company.

In case of type 2 diabetes insulin is secreted in patient’s body but it is not effective to reduce blood glucose due to resistance developed by insulin receptors in the body tissue or it could be other way that the amount of insulin required is greater than usual. There are many reasons for insulin resistance, like obesity, higher body weight, lower physical activity and stress.

Drug Dulaglutide should not be used in treatment of type 1 diabetes, and patients with increased ketone in their blood. Also a patient with family history of medullary thyroid carcinoma (MTC) should not be given this drug.

US FDA have approved this drug with medullary thyroid carcinoma (MTC) that requires a plan for communication system to inform risks and monitor adverse effects.
There are few conditions laid down by US FDA in order to monitor safety of drug approved, as follows.

No comments:

Post a Comment

Enter your email address:

Enter your email address: